Filtered By:
Drug: Cipro
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 5398 results found since Jan 2013.
Prevalence of ESBL-Producing < em > Enterobacter < /em > Species Resistant to Carbapenems in Iran: A Systematic Review and Meta-Analysis
CONCLUSION: In accordance with the warning of international organizations, our results revealed a high prevalence of ESBL-producing Enterobacter species in Iran, which is probably associated with the high prevalence of Enterobacter species resistant to most of the assessed antibiotics, especially MDR strains. However, the resistance rate to carbapenems was relatively low, and these drugs can still be considered as drugs of choice for the treatment of Enterobacter infections in Iran. Nevertheless, continuous monitoring of drug resistance along with antibiotic therapy based on the local data and evaluation of the therapeutic...
Source: International Journal of Microbiology - October 31, 2022 Category: Microbiology Authors: Farzad Khademi Hamid Vaez Zohreh Neyestani Amirhossein Sahebkar Source Type: research
Prenylated phenolics from Morus alba against MRSA infections as a strategy for wound healing
In conclusion, prenylated phenolics in combination with commonly used antibiotics are promising candidates for the treatment of MRSA infections and wound healing, although further studies are needed.
Source: Frontiers in Pharmacology - November 30, 2022 Category: Drugs & Pharmacology Source Type: research
The increasing antimicrobial resistance of < em > Shigella < /em > species among Iranian pediatrics: a systematic review and meta-analysis
CONCLUSION: Our findings revealed that ciprofloxacin is an effective drug for shigellosis in Iranian children. The substantially high prevalence estimation proposes that the first- and second-line treatments for shigellosis are the major threat to public health and active antibiotic treatment policies are essential.PMID:36794800 | DOI:10.1080/20477724.2023.2179451
Source: Pathogens and Global Health - February 16, 2023 Category: International Medicine & Public Health Authors: Amirhossein Baharvand Leila Molaeipour Sogol Alesaeidi Reyhane Shaddel Noushin Mashatan Taghi Amiriani Melika Kiaei Sudkolaei Sara Abbasian Bashar Zuhair Talib Al-Naqeeb Ebrahim Kouhsari Source Type: research
Bioactive metabolites of Streptomyces misakiensis display broad-spectrum antimicrobial activity against multidrug-resistant bacteria and fungi
ConclusionS. misakiensis metabolite extracts are broad-spectrum antimicrobial biomaterials that can be further investigated for the potential against MDR pathogen infections. Hence, it opens up new horizons for exploring alternative drugs for current and reemerging diseases.
Source: Frontiers in cellular and infection microbiology - April 24, 2023 Category: Microbiology Source Type: research
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism
Expert Opin Drug Saf. 2023 Aug 18:1-6. doi: 10.1080/14740338.2023.2245748. Online ahead of print.ABSTRACTINTRODUCTION: Nuclear reactor incidents and bioterrorism outbreaks are concerning public health disasters. Little is known about US Food and Drug Administration (FDA)-approved agents that can mitigate consequences of these events. We review FDA data supporting regulatory approvals of these agents.AREAS COVERED: We reviewed pharmaceutical products approved to treat Hematopoietic Acute Radiation Syndrome (H-ARS) and to treat or prevent pulmonary infections following Bacillus anthracis (anthrax) exposure. Four drugs were a...
Source: Expert Opinion on Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Charles L Bennett Peter Georgantopoulos Robert Peter Gale Kevin Knopf William J Hrushesky Chadi Nabhan James O Armitage Source Type: research
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
We examined whether respiratory symptoms improved during on-treatment periods and the relationship of changes in QOL-B-RSS to changes in bacterial load using a mixed-model repeated measures approach.
ARD-3150 treatment resulted in a significant improvement in respiratory symptoms during the on-treatment periods with concordant results between ORBIT-3 (estimate 1.4 points, se 0.49; p=0.004) and ORBIT-4 (estimate 1.1 point, se 0.41; p=0.006). The proportion of patients achieving a symptom improvement above the minimum clinically important difference was higher with ARD-3150 compared with placebo during on-treatment cycles (p...
Source: European Respiratory Journal - October 22, 2020 Category: Respiratory Medicine Authors: Chalmers, J. D., Cipolla, D., Thompson, B., Davis, A. M., O'Donnell, A., Tino, G., Gonda, I., Haworth, C., Froehlich, J. Tags: CF and non-CF bronchiectasis Original Articles: Bronchiectasis Source Type: research
Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
Conclusion: Inhaled ARD-3150 resulted in significant improvements in respiratory symptoms during the on-treatment periods which were lost during off-treatment periods.
Source: European Respiratory Journal - October 28, 2020 Category: Respiratory Medicine Authors: Chalmers, J. D., Cipolla, D., Thompson, B., Davis, A. M., O'Donnell, A., Tino, G., Gonda, I., Haworth, C., Froehlich, J. Tags: Respiratory infections Source Type: research
Light-Controlled Active Release of Photocaged Ciprofloxacin for Lipopolysaccharide-Targeted Drug Delivery using Dendrimer Conjugates
We report... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - July 27, 2016 Category: Chemistry Authors: Pamela Wong Source Type: research
